Efficacy and toxicity of apatinib combined with or without chemotherapy for patients with advanced or metastatic chemotherapy-refractory gastric adenocarcinoma: A prospective clinical study

Apatinib (Jiangsu HengRui Medicine Co. Ltd), a vascular endothelial growth factor receptor 2 (VEGFR-2) tyrosine kinase inhibitor, has been proven to be safe and to significantly prolong survival in advanced chemotherapy-refractory gastric cancer. This study aimed to assess and compare the efficacy a...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Yesong, Tang, Jinhai, Huang, Xin-En, Cao, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6380695/
https://www.ncbi.nlm.nih.gov/pubmed/30732125
http://dx.doi.org/10.1097/MD.0000000000013908

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6380695/
https://www.ncbi.nlm.nih.gov/pubmed/30732125
http://dx.doi.org/10.1097/MD.0000000000013908

Ejemplares similares